Antagonists of IL-6 to raise albumin and/or lower CRP
AssigneeAlderbio Holdings LLC
InventorJeffrey T. L. Smith
Life of this patent
Estimating the term…
Abstract
The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved.
Claims19
A method of reducing a patient's serum C-reactive protein (“CRP”) level and/or increasing human serum albumin (“HSA”) level in a patient that has a disease associated with chronic inflammation comprising administering a therapeutically effective amount of an antibody or antibody fragment comprising a light chain comprising CDR polypeptides having the amino acid sequences of SEQ ID NO:
- 4, 5 and 6;
- and a heavy chain comprising CDR polypeptides having the amino acid sequences of SEQ ID NO:
- 7, 8 or 120 and 9.
Dependencies are inferred from the claim text.